Olema Pharmaceuticals, Inc.
OLMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $39,951 | $43,902 | $30,624 | $32,299 |
| G&A Expenses | $5,926 | $3,962 | $4,249 | $4,469 |
| SG&A Expenses | $5,926 | $3,962 | $4,249 | $4,469 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $45,877 | $47,864 | $34,873 | $36,768 |
| Operating Income | -$45,877 | -$47,864 | -$34,873 | -$36,768 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,660 | $4,080 | $4,484 | $3,201 |
| Pre-Tax Income | -$42,217 | -$43,784 | -$30,389 | -$33,567 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$42,217 | -$43,784 | -$30,389 | -$33,567 |
| % Margin | – | – | – | – |
| EPS | -0.49 | -0.51 | -0.36 | -0.57 |
| % Growth | 3.9% | -41.7% | 36.8% | – |
| EPS Diluted | -0.49 | -0.51 | -0.36 | -0.57 |
| Weighted Avg Shares Out | 85,732 | 85,497 | 85,426 | 58,744 |
| Weighted Avg Shares Out Dil | 85,732 | 85,497 | 85,426 | 58,744 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,648 | $4,042 | $4,524 | $3,294 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $43 | $132 | $128 | $116 |
| EBITDA | -$42,174 | -$47,732 | -$34,745 | -$36,652 |
| % Margin | – | – | – | – |